Insider · CIK 0001444319

Nunn Jason Raleigh

Reports to the SEC for 8 companies · GENEVA

sec.gov

Transactions

Companies

Filings

CIK

0001444319

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-02	ADXNAddex Therapeutics Ltd.D Disposition to Issuer	Director	DDisposition to Issuer	−220K sh	—	—	0
2026-09-02	ADXNAddex Therapeutics Ltd.A Award	Director	AAward	+220K sh	—	—	219,561
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−50K sh	—	—	0
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)A Award	Director	AAward	+50K sh	—	—	50,000
2026-06-15	ZBIOZenas BioPharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.5K sh	—	—	18,500
2025-10-09	ZBIOZenas BioPharma, Inc.P Purchase	Director	PPurchase	+63.2K sh	$19.00	+$1.2M	1,173,395
2025-06-25	Regulus Therapeutics Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−62.5K sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Director	DDisposition to Issuer	−4,650 sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Director	DDisposition to Issuer	−2,325 sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Director	DDisposition to Issuer	−4,000 sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Director	DDisposition to Issuer	−9,000 sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Director	DDisposition to Issuer	−30K sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Director	DDisposition to Issuer	−30K sh	—	—	0
2025-06-25	Regulus Therapeutics Inc.Stock OptionD Disposition to Issuer	Director	DDisposition to Issuer	−60K sh	—	—	0
2025-06-10	ZBIOZenas BioPharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.5K sh	—	—	18,500
2025-04-30	Regulus Therapeutics Inc.A Award	Director	AAward	+62.5K sh	—	—	62,500
2024-09-16	ZBIOZenas BioPharma, Inc.C Conversion	Director	CConversion	+1.51M sh	—	—	1,505,388
2024-09-16	ZBIOZenas BioPharma, Inc.P Purchase	Director	PPurchase	+441K sh	$17.00	+$7.5M	1,946,564
2024-09-16	ZBIOZenas BioPharma, Inc.C Conversion	Director	CConversion	+669K sh	—	—	669,061
2024-09-16	ZBIOZenas BioPharma, Inc.P Purchase	Director	PPurchase	+441K sh	$17.00	+$7.5M	1,110,237
2024-09-16	ZBIOZenas BioPharma, Inc. · Series C Convertible Preferred StockC Conversion	Director	CConversion	−13.1M sh	—	—	0
2024-09-16	ZBIOZenas BioPharma, Inc. · Series C Convertible Preferred StockC Conversion	Director	CConversion	−5.81M sh	—	—	0
2024-09-12	ZBIOZenas BioPharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+37K sh	—	—	37,000
2024-06-13	TREVENA INCStock Option (Right to Buy)A Award	Director	AAward	+13.7K sh	—	—	13,700
2024-05-20	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Director	AAward	+60K sh	—	—	60,000
2024-05-16	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2023-08-10	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2023-06-15	TREVENA INCStock Option (Right to Buy)A Award	Director	AAward	+13.7K sh	—	—	13,700
2023-06-13	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2022-06-09	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Director	AAward	+90K sh	—	—	90,000
2022-06-09	TREVENA INCStock Option (Right to Buy)A Award	Director	AAward	+100K sh	—	—	100,000
2021-06-14	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2021-05-28	TREVENA INCStock Option (Right to Buy)A Award	Director	AAward	+68.6K sh	—	—	68,577
2020-06-17	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Director	AAward	+23.3K sh	—	—	23,250
2020-05-13	TREVENA INCStock Option (Right to Buy)A Award	Director	AAward	+64.1K sh	—	—	64,103
2020-02-20	Dermira, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−6,000 sh	$18.75	−$113K	0
2020-02-20	Dermira, Inc.Director Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10.3K sh	—	—	0
2020-02-20	Dermira, Inc.Director Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10.3K sh	—	—	0
2020-02-20	Dermira, Inc.Director Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,000 sh	—	—	0
2020-02-20	Dermira, Inc.Director Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,000 sh	—	—	0
2020-02-20	Dermira, Inc.Director Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,000 sh	—	—	0
2020-02-20	Dermira, Inc.Restricted Stock UnitD Disposition to Issuer	Director	DDisposition to Issuer	−3,000 sh	—	—	0
2019-10-10	Regulus Therapeutics Inc.Stock Option (Right to Buy)A Award	Director	AAward	+46.5K sh	—	—	46,500
2019-06-12	Dermira, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,000 sh	—	—	6,000
2019-06-12	Dermira, Inc.Common StockM Exercise/Conversion	Director	MExercise/Conversion	−3,000 sh	—	—	0
2019-06-04	Dermira, Inc.Director Stock Option (right to buy)A Award	Director	AAward	+6,000 sh	—	—	6,000
2019-06-04	Dermira, Inc.Restricted Stock UnitA Award	Director	AAward	+3,000 sh	—	—	3,000
2019-05-16	TREVENA INCStock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2018-06-13	Dermira, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,000 sh	—	—	3,000

Recent filings

Accepted (ET)
Sep 44
Nunn Jason Raleigh0001104659-26-105501
SEC(opens sec.gov)
Jun 174
Nunn Jason Raleigh0001193125-26-274473
SEC(opens sec.gov)
Oct 144
Nunn Jason Raleigh0001193125-25-239158
SEC(opens sec.gov)
Jun 274
Nunn Jason Raleigh0000950170-25-091006
SEC(opens sec.gov)
Jun 124
Nunn Jason Raleigh0000950170-25-085531
SEC(opens sec.gov)
Apr 304
Nunn Jason Raleigh0000950170-25-061298
SEC(opens sec.gov)
Sep 164
Nunn Jason Raleigh0000950170-24-106979
SEC(opens sec.gov)

Companies

Address

CHEMIN DES MINES 9

GENEVA, CH-1202